Lilly to Supply U.S. up to 600k Bebtelovimab Doses for $720m

Eli Lilly and Company said it has agreed to supply the U.S. up to 600,000 doses of the investigational Covid-19 drug bebtelovimab for at least $720 million.

• Lilly said the U.S. will accept the doses if the drug is granted an EUA by the FDA
  • Lilly has submitted a request for an EUA
• The deal calls for the delivery of up to 600,000 doses no later than March 31, with an option of 500,000 additional doses no later than July 31
• Lilly said the estimated financial impact is approx. $0.20 of EPS

To view the source of this information click ...